{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~32 mi. (Denison, Texas, +192 more cities)
facility
Texas Oncology - Denison
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy
city
~32 mi. (Denison, Texas, +17 more cities)
facility
Texas Oncology - Denison
drug type
chemotherapy, +1 more type
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~34 mi. (Sherman, Texas, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
city
~49 mi. (McKinney, Texas, +89 more cities)
facility
Texas Oncology McKinney
biomarker
ER Positive, +1 more biomarker
drug
giredestrant, +1 more drug